Toggle Contrast

Evaluating the Cancer Vanguard

The Cancer Vanguard was established to pilot and roll out new models of care that would provide innovative high quality cancer care across the whole patient pathway. The Vanguard as a formal collaboration ended at the end of March 2018.

Over the last 18 months, the Cancer Vanguard has been working with external evaluators from Technopolis Group and Optimity Advisors to determine the impact of its work on cancer outcomes and patient experience; the value delivered across all three Vanguard partners; and whether the work can be replicated.

For more information about the evaluation, and to download the evaluation report and executive summary, go to the Cancer Vanguard website.